Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By

Showing results 31 - 40 of 75

Selected Filters:
7 July 2022

Talk to Your Doctor about PrEP

This pamphlet provides advice on discussing PrEP with your doctor.

Demand Creation/Marketing

External Link
7 July 2022

The Power of Demand Generation

Demand generation increases awareness of and demand for health products or services among a particular intended audience through social and behavior change communication and social marketing techniques. This learning module outlines the key concepts and definitions of demand generation.

Demand Creation/Marketing

External Link
7 July 2022

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

This study compares the effectiveness and cost-effectiveness of providing antiretroviral therapy vs PrEP in South Africa

Financing & Costing

External Link
7 July 2022

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

This study estimates the cost-effectiveness of daily oral PrEP, with a protective effect against the herpes simplex virus as well as HIV, among HIV serodifferent couples in South Africa

Financing & Costing

External Link
7 July 2022

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

External Link
7 July 2022

WHO PrEP Implementation Tool App

The Oral PrEP eLearning Resource Package (eLRP) introduces health care providers to Oral PrEP for HIV infection. The eLRP includes eLearning courses for clinicians with an accompanying Oral PrEP Implementation Tool App.

Normative Guidance/Policies

External Link
7 July 2022

Microbicide Trials Network-043 – B-PROTECTED Study

Microbicide Trials Network-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring and daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV.

Research

External Link
7 July 2022

An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP

Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and…

Community/Advocacy

External Link
7 July 2022

Results from the HPTN 083 Trial

The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…

Research

External Link
7 July 2022

HPTN 084

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

External Link